文献速递胸部CT

临床I期非小细胞肺癌中微小(≤10%)磨玻璃密度成分与病理特征及临床结局的关联

Minor (≤ 10%) Ground-Glass Opacity Component in Clinical Stage I Non-Small Cell Lung Cancer: Associations With Pathologic Characteristics and Clinical Outcomes.
PubMed 文献 · AJR Am J Roentgenol · 2024-05-29

回顾性纳入382例术前胸部CT表现为实性为主结节(实性成分占比0.9–1.0)的临床I期非小细胞肺癌手术患者,比较微小磨玻璃成分组(106例)与纯实性组(276例)。微小磨玻璃成分组5年无复发生存率83.4%(纯实性组55.0%),多因素分析中微小磨玻璃成分与复发风险降低独立相关(HR=0.37)。

要点

  • 实性为主结节中即使仅≤10%的磨玻璃成分也提示预后较好。
  • 微小磨玻璃成分组5年无复发生存率83.4%,纯实性组55.0%。
  • 阅片时应仔细识别实性结节中极微小的磨玻璃成分。

核心结论

  • 临床I期非小细胞肺癌中,含微小磨玻璃成分者预后优于纯实性表现者,且微小磨玻璃成分与复发风险降低独立相关(HR=0.37),但与肿瘤特异性生存无独立关联。

研究设计与样本

  • 回顾性研究,纳入2015年1月1日至2015年12月31日接受手术切除的382例临床I期非小细胞肺癌患者(平均年龄60.8岁,男210例、女172例),术前胸部CT示结节实性成分占比0.9–1.0;由两名放射科医生独立分组,采用Kaplan-Meier曲线、log-rank检验及Cox比例风险模型分析。

关键影像表现/征象

  • 微小磨玻璃成分组实性成分直径2.68 cm大于纯实性组的2.16 cm(p<.001)。
  • 微小磨玻璃成分组总结节直径2.89 cm大于纯实性组的2.16 cm(p<.001)。
  • 微小磨玻璃成分组平均实性成分占比为0.93±0.02(标准差)(范围0.90–0.97)。

诊断标准与关键数值

  • 微小磨玻璃成分组定义为实性成分占比≥0.9且<1.0,纯实性组定义为实性成分占比=1.0。
  • 两名放射科医生对全部结节的分组判断一致。
  • 微小磨玻璃成分组5年无复发生存率83.4% vs 纯实性组55.0%(p<.001)。
  • 微小磨玻璃成分组5年肿瘤特异性生存率92.4% vs 纯实性组76.4%(p=.004)。
  • 多因素分析中微小磨玻璃成分与复发风险降低独立相关(HR=0.37,p=.001),与肿瘤特异性生存无独立关联。

临床应用与阅片要点

  • 放射科医生在CT上遇到以实性为主的结节时,应仔细评估图像以识别即使微小的磨玻璃成分,因其提示预后较好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The presence of a ground-glass opacity (GGO) component is a favorable prognostic factor in non-small cell lung cancer (NSCLC), although the prognostic impact of a very small GGO component remains poorly investigated. OBJECTIVE. The purpose of this article is to investigate the impact of a minor (≤ 10%) GGO component on the prognosis of clinical stage I NSCLC in comparison with pure-solid nodules. METHODS. This retrospective study included 382 patients (mean age, 60.8 years; 210 men, 172 women) who underwent surgical resection between January 1, 2015, and December 31, 2015, for clinical stage I NSCLC appearing on preoperative chest CT as a nodule with a consolidation-to-tumor ratio (CTR) of 0.9 to 1.0. Two radiologists independently assigned nodules to groups as either minor GGO (CTR, ≥ 0.9 and < 1.0) or pure solid (CTR = 1.0). Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed by Kaplan-Meier curves and compared between groups using log-rank tests. Cox proportional hazards models were used to assess associations with outcomes. RESULTS. The two radiologists agreed for all nodules' classification into the minor-GGO (n = 106) or pure-solid (n = 276) groups. The mean CTR of the minor-GGO group was 0.93 ± 0.02 (SD) (range, 0.90-0.97). Minor-GGO nodules, in comparison with pure-solid nodules, showed greater solid-component diameter (2.68 vs 2.16 cm; p < .001) and total nodule diameter (2.89 vs 2.16 cm; p < .001). The minor-GGO group, in comparison with the pure-solid group, showed lower frequencies of visceral pleural invasion (6.6% vs 17.0%, p = .009) and pathologic lymph node involvement (4.7% vs 20.3%, p < .001), and EGFR mutation (71.6% vs 39.9%; p < .001). The minor-GGO group, in comparison with the pure-solid group, showed better 5-year RFS (83.4% vs 55.0%; p < .001) and higher frequency of better 5-year CSS (92.4% vs 76.4%, p = .004). In multivariable analysis adjusting for patient, imaging, pathologic, and genetic factors, a minor-GGO component was independently associated with a decreased likelihood of recurrence (HR = 0.37, p = .001) but not with the likelihood of CSS. CONCLUSION. Among patients with clinical stage I NSCLC, cancers with a minor-GGO component were associated with a better prognosis versus those with a pure-solid appearance. CLINICAL IMPACT. Radiologists encountering predominantly solid nodules on CT should carefully assess images for even a minor-GGO component given the favorable prognosis.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Li M, Wang J, Bao X, et al. Minor (≤ 10%) Ground-Glass Opacity Component in Clinical Stage I Non-Small Cell Lung Cancer: Associations With Pathologic Characteristics and Clinical Outcomes. AJR Am J Roentgenol. 2024. PMID: 38809121. doi:10.2214/AJR.24.31283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。